Searched for: subject:"diabetic%5C+nephropathy"
(1 - 6 of 6)
document
van den Berg, E. (author), Hospers, F.A.P. (author), Navis, G. (author), Engberink, M.F. (author), Brink, E.J. (author), Geleijnse, J.M. (author), van Baak, M.A. (author), Gans, R.O.B. (author), Bakker, S.J.L. (author)
Diabetic nephropathy is now the most common cause of end-stage renal failure in many countries of the world. Despite increasing implementation of preventive treatment, the chance that an individual diabetic patient will reach end-stage renal failure has been increasing rather than decreasing during recent decades. Current dietary habits in The...
article 2011
document
van der Zijl, N.J. (author), Hanemaaijer, R. (author), Tushuizen, M.E. (author), Schindhelm, R.K. (author), Boerop, J. (author), Rustemeijer, C. (author), Bilo, H.J. (author), Verheijen, J.H. (author), Diamant, M. (author), TNO Kwaliteit van Leven (author)
Matrix metalloproteinases (MMPs) may play a pathophysiological role in the development of diabetic nephropathy (DN). We hypothesized that urinary MMP activity in patients with type 2 diabetes mellitus (T2DM) is related to a decline in renal function. We determined MMP-2, -8 and -9 activity in 24-h urine collections in relation to risk factors...
article 2010
document
Myrup, B. (author), Rossing, P. (author), Jensen, T. (author), Gram, J. (author), Kluft, C. (author), Jespersen, J. (author), Gaubius instituut TNO (author)
Objective: To investigate protein concentration changes during venous occlusion of proteins with reported affinity for extracellular matrix (plasminogen activator inhibitor type 1, antithrombin III, fibronectin and von Willebrand factor) in comparison with proteins with no reported affinity (albumin, tissue-type plasminogen activator,...
article 1999
document
Schalkwijk, C.G. (author), Ligtvoet, N. (author), Twaalfhoven, H. (author), Jager, A. (author), Blaauwgeers, H.G.T. (author), Schlingemann, R.O. (author), Tarnow, L. (author), Parving, H.H. (author), Stehouwer, C.D.A. (author), van Hinsbergh, V.W.M. (author), Gaubius instituut TNO (author)
Nonenzymatic glycation is increased in diabetes. Most studies so far have focused on the role of advanced glycation end products (AGEs) in vascular complications, whereas the role of early glycation Amadori-modified proteins, which is the predominant form of glycated proteins, has not been systemically investigated in humans. We developed an...
article 1999
document
Fioretto, P. (author), Stehouwer, C.D.A. (author), Mauer, M. (author), Chiesura-Corona, M. (author), Brocco, E. (author), Carraro, A. (author), Bortoloso, E. (author), van Hinsbergh, V.W.M. (author), Crepaldi, G. (author), Nosadini, R. (author), Gaubius Instituut TNO (author)
Microalbuminuria (MA) is associated with microangiopathy (renal and retinal lesions) in insulin-dependent diabetic (IDDM) patients. In contrast MA does not reflect microvascular damage in a substantial number of non- insulin-dependent diabetic (NIDDM) patients. MA predicts cardiovascular disease in NIDDM patients with increased von Willebrand...
article 1998
document
Myrup, B. (author), Jensen, T. (author), Gram, J. (author), Kluft, C. (author), Jespersen, J. (author), Deckert, T. (author), Gaubius Instituut TNO (author)
OBJECTIVE - The high risk for cardiovascular disease in IDDM patients with nephropathy may be mediated by abnormal function of the vascular wall. We investigated whether heparin was able to modulate markers of vascular wall and hemostatic function in patients with incipient nephropathy. RESEARCH DESIGN AND METHODS - Thirty-five IDDM patients...
article 1997
Searched for: subject:"diabetic%5C+nephropathy"
(1 - 6 of 6)